Sensei Biotherapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -3.62, beating the estimate of USD -4.11.

Cash Position

Cash, cash equivalents, and marketable securities were $25.0 million as of September 30, 2025, compared to $41.3 million as of December 31, 2024.

Research and Development (R&D) Expenses

R&D expenses were $2.5 million for the quarter ended September 30, 2025, compared to $4.6 million for the quarter ended September 30, 2024. The decrease was primarily due to lower personnel and facilities costs, and reduced lab supply costs.

General and Administrative (G&A) Expenses

G&A expenses were $2.3 million for the quarter ended September 30, 2025, compared to $3.2 million for the quarter ended September 30, 2024. The decrease was mainly due to lower personnel costs.

Net Loss

Net loss was $4.6 million for the quarter ended September 30, 2025, compared to $7.3 million for the quarter ended September 30, 2024.

Total Assets and Liabilities

Total assets were $27.6 million as of September 30, 2025, compared to $45.4 million as of December 31, 2024. Total liabilities were $4.6 million as of September 30, 2025, compared to $7.0 million as of December 31, 2024.

Outlook / Guidance

The company announced the discontinuation of solnerstotug development and is exploring strategic alternatives to maximize shareholder value, which may include asset sales, licensing, collaborations, or a sale of the company. A workforce reduction of approximately 65% has been implemented to preserve cash while retaining a small team to assist in exploring these strategic alternatives.